This agreement further strengthens the collaboration between the companies that began with the development and commercialization agreement for PTH1-34 nasal spray that was announced in February.
Under terms of the supply agreement, Nastech will be the exclusive manufacturer of the PTH1-34 nasal spray for P&G and will be responsible for the chemistry, manufacturing and controls sections of the FDA regulatory submission.
Nastech will supply the compound to P&G at a transfer price that includes a manufacturing profit. Specific financial terms of the agreement were not disclosed.
“We are excited to have completed the supply agreement with Nastech as it secures sufficient manufacturing capacity to meet expected global demand upon commercialization of PTH1-34 nasal spray, if approved,” said Mark Collar, global president of pharmaceuticals and personal health, Procter & Gamble.